Comprehensive Analysis of Prognostic Factors in Advanced Gastric Cancer Patients Treated with Chemotherapy

被引:4
|
作者
Cavdar, Eyyup [1 ]
Iriagac, Yakup [1 ]
Avci, Okan [1 ]
Seber, Erdogan Selcuk [1 ]
机构
[1] Tekirdag Namik Kemal Univ, Dept Med Oncol, Tekirdag, Turkey
关键词
Gastric cancer; Prognosis; Overall survival; Chemotherapy; Metastasis; Prognostic biomarkers; TO-LYMPHOCYTE RATIO; PREDICTS SURVIVAL; INDEX; INDICATOR;
D O I
10.29271/jcpsp.2022.11.1420
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the strongest prognostic factors in advanced gastric cancer. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, Tekirdag Namik Kemal University, Tekirdag, Turkey, between March 2012 and April 2022. Methodology: Adult patients with metastatic cancer who had completed at least two months of chemotherapy, without any other comorbidity were included. Using Kaplan-Meier methodology and Cox regression methods, potential prognostic factors were analysed for overall survival. Two different models were created for multivariate analysis by using statistically significant factors in univariate analysis. Results: The median overall survival in 216 patients was 7.8 months. The univariate analysis showed that body-mass index, performance status, liver metastasis, albumin, gamma-glutamyl transferase, carcinoembryonic antigen, carbohydrate antigen (CA 19-9), neutrophil-lymphocyte ratio (NLR), systemic immune-inflammation index, albumin-to-alkaline phosphatase ratio, sodium-globulin ratio (SGR) prognostic nutritional index (PNI), albumin-bilirubin ratio, and albumin-globulin ratio were associated with survival. In Model 1, which included only laboratory indices, multivariate analyses revealed that NLR (p= 0.001), SGR (p=0.025), and PNI (p=0.032) were prognostic for overall survival. In Model 2, established with all parameters, NLR (p=0.003), albumin (p=0.003), performance status (p<0.001), and CA 19-9 (p<0.001) were found to be independent prognostic factors. Conclusion: Pretreatment NLR, SGR, PNI, albumin, performance status, and CA 19-9 are strong prognostic factors in patients with advanced gastric cancer. These prognostic factors, which are easily accessible in clinical practice, may be utilised as useful tools for clinicians.
引用
收藏
页码:1420 / 1424
页数:5
相关论文
共 50 条
  • [1] Prognostic factors for survival in patients with advanced gastric cancer treated with chemotherapy.
    Mangas, Montserrat
    Carmona Bayonas, Alberto
    Sanchez Lorenzo, Maria Luisa
    Ramchandani, Avinash
    Garcia, Teresa
    Custodio, Ana B.
    Lorenzo Barreto, Jose Enrique
    Diaz Guardamino, Isabel Echavarria
    Diaz Serrano, Asuncion
    Maria Cano, Juana
    Azkarate, Aitor
    Longo, Federico
    Mugica, Maitane
    Sanchez, Rodrigo
    Serrano, Raquel
    Alvarez Mancenido, Felipe Jose
    Alsina, Maria
    Jimenez-Fonseca, Paula
    Garrido, Marcelo
    Gallego Plazas, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Prognostic factors in advanced gastric cancer patients (PTS) treated with a second-line chemotherapy
    Catalano, V
    Graziano, F.
    Santini, D.
    D'Emidio, S.
    Baldelli, A.
    Vincenzi, B.
    Giordani, P.
    Rossi, D.
    Alessandroni, P.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2007, 18 : VII24 - VII25
  • [3] Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
    Kim, Jong Gwang
    Ryoo, Baek-Yeol
    Park, Yeon Hee
    Kim, Bong-Seog
    Kim, Tae-You
    Im, Young-Hyuck
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (02) : 301 - 307
  • [4] Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
    Jong Gwang Kim
    Baek-Yeol Ryoo
    Yeon Hee Park
    Bong-Seog Kim
    Tae-You Kim
    Young-Hyuck Im
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 301 - 307
  • [5] Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: A multivariate analysis
    Tsujitani, S
    Oka, S
    Suzuki, K
    Saito, H
    Kondo, A
    Ikeguchi, M
    Maeta, M
    Kaibara, N
    HEPATO-GASTROENTEROLOGY, 2001, 48 (41) : 1504 - 1508
  • [6] Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy
    Ishii, H
    Okada, S
    Nose, H
    Yoshimori, M
    Aoki, K
    Okusaka, T
    PANCREAS, 1996, 12 (03) : 267 - 271
  • [7] Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection
    Sun, Yongkun
    Yang, Lin
    Wang, Chengfeng
    Zhao, Dongbing
    Cai, Jianqiang
    Li, Wenbin
    Zhang, Wen
    Huang, Jing
    Zhou, Aiping
    ONCOTARGET, 2017, 8 (43) : 75186 - 75194
  • [8] Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
    Fanotto, Valentina
    Cordio, Stefano
    Pasquini, Giulia
    Fontanella, Caterina
    Rimassa, Lorenza
    Leone, Francesco
    Rosati, Gerardo
    Santini, Daniele
    Giampieri, Riccardo
    Di Donato, Samantha
    Tomasello, Gianluca
    Silvestris, Nicola
    Pietrantonio, Filippo
    Battaglin, Francesca
    Avallone, Antonio
    Scartozzi, Mario
    Lutrino, Eufemia Stefania
    Melisi, Davide
    Antonuzzo, Lorenzo
    Pellegrino, Antonio
    Torri, Valter
    Aprile, Giuseppe
    GASTRIC CANCER, 2017, 20 (05) : 825 - 833
  • [9] Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
    Valentina Fanotto
    Stefano Cordio
    Giulia Pasquini
    Caterina Fontanella
    Lorenza Rimassa
    Francesco Leone
    Gerardo Rosati
    Daniele Santini
    Riccardo Giampieri
    Samantha Di Donato
    Gianluca Tomasello
    Nicola Silvestris
    Filippo Pietrantonio
    Francesca Battaglin
    Antonio Avallone
    Mario Scartozzi
    Eufemia Stefania Lutrino
    Davide Melisi
    Lorenzo Antonuzzo
    Antonio Pellegrino
    Valter Torri
    Giuseppe Aprile
    Gastric Cancer, 2017, 20 : 825 - 833
  • [10] Neoadjuvant chemotherapy for advanced gastric cancer; combined analysis to explore prognostic factors
    Terashima, M.
    Satoh, S.
    Okabe, H.
    Hosotani, R.
    Saze, Z.
    Teramukai, S.
    Sakabayashi, S.
    Kusunoki, Y.
    Sakai, Y.
    Gotoh, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S590 - S591